Bioxytran Inc. (BIXT)
Market Closed
10 Aug, 20:00
OTCQB OTCQB Primary $
0. 02
-0
-16.7963%
$
2.54M Market Cap
- P/E Ratio
- Div Yield
171,005 Volume
- Eps
$ 0.03
Previous Close Want to track BIXT and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Bioxytran's Medical Breakthrough in Fighting All Viruses
Breakthrough was validated in the latest journal article Galectins are essential for viral entry and a new target for drug development Carbohydrates were shown to neutralize viruses Blocking galectins could be the most efficient way to prevent and treat viruses potentially impacting the vaccination and antiviral markets BOSTON, MA / ACCESSWIRE / September 19, 2024 / BIOXYTRAN, INC. (OTCQB:BIXT) (the "Company"), a clinical stage biotechnology company developing drugs to treat stroke and Alzheimer's disease, announced a medical breakthrough in virology that was validated in a peer-reviewed medical journal article.
Accesswire | 1 year ago
